Arcus Biosciences Inc.

6 days ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

13 days ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company's common stock at an exercise price per share of $29.06, which was the.

13 days ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

27 days ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2026 Biotech Back to School Conference Date: Wednesday, September 9th, 2026 Location: New York, NY Format: Fireside chat &amp.

1 month ago · prnewswire.com

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS)  breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

2 months ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to break-even earnings per share a year ago.

2 months ago · businesswire.com

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.

2 months ago · businesswire.com

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, August 5th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended June 30th, 20.

2 months ago · benzinga.com

HC Wainwright raised its price forecast for Arcus Biosciences Inc. (NASDAQ:RCUS), citing the aggressive push into 1L clear cell renal cell carcinoma (ccRCC) development.